AUGMENTIN XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Augmentin Xr, and when can generic versions of Augmentin Xr launch?
Augmentin Xr is a drug marketed by Us Antibiotics and is included in one NDA.
The generic ingredient in AUGMENTIN XR is amoxicillin; clavulanate potassium. There are forty-six drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the amoxicillin; clavulanate potassium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Augmentin Xr
A generic version of AUGMENTIN XR was approved as amoxicillin; clavulanate potassium by SANDOZ on March 14th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AUGMENTIN XR?
- What are the global sales for AUGMENTIN XR?
- What is Average Wholesale Price for AUGMENTIN XR?
Summary for AUGMENTIN XR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 15 |
| Clinical Trials: | 75 |
| Patent Applications: | 705 |
| Drug Prices: | Drug price information for AUGMENTIN XR |
| DailyMed Link: | AUGMENTIN XR at DailyMed |
Recent Clinical Trials for AUGMENTIN XR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Daniel Merenstein | Phase 4 |
| University of California, Los Angeles | Phase 4 |
| Medstar Health Research Institute | Phase 4 |
Paragraph IV (Patent) Challenges for AUGMENTIN XR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AUGMENTIN XR | Extended-release Tablets | amoxicillin; clavulanate potassium | 1000 mg/62.5 mg | 050785 | 1 | 2009-01-21 |
US Patents and Regulatory Information for AUGMENTIN XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AUGMENTIN XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Us Antibiotics | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AUGMENTIN XR
See the table below for patents covering AUGMENTIN XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Belgium | 1013309 | FORMULATIONS PHARMACEUTIQUES NOUVELLES COMPRENANT L'AMOXYCILLINE ET DU CLAVULANATE DE POTASSIUM. | ⤷ Sign Up |
| Mexico | PA01010376 | METODO NOVEDOSO DE TRATAMIENTO.. (NOVEL METHOD OF TREATMENT.) | ⤷ Sign Up |
| African Intellectual Property Organization (OAPI) | 11926 | Novel method of treatment | ⤷ Sign Up |
| European Patent Office | 1270005 | ⤷ Sign Up | |
| Belgium | 1012733 | FORMULATIONS PHARMACEUTIQUES NOUVELLES COMPRENANT L'AMOXYCILLINE ET DU CLAVULANATE DE POTASSIUM. | ⤷ Sign Up |
| Finland | 4823 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
